Metoprolol 0.K. Abz (Metoprolol Tartrate)

• Metoprolol Tartrate is used in cardiovascular disease management, targeting conditions that benefit from reduced heart rate and myocardial oxygen demand.
• Hypertension: lowers systemic blood pressure by decreasing cardiac output and renin release.
• Angina pectoris: alleviates chest pain by reducing myocardial oxygen consumption.
• Post‑myocardial infarction: improves survival and reduces the risk of recurrent ischemic events.
• Chronic heart failure: enhances ventricular function and decreases hospitalisation rates.

• Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors located primarily in cardiac tissue. By blocking the action of endogenous catecholamines on these receptors, it reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure. The β1‑selectivity limits effects on β2 receptors, preserving bronchial and peripheral vascular tone. These pharmacodynamic actions translate into therapeutic control of hypertension and ischemic heart conditions.

Metoprolol Tartrate may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially on standing.
• Gastrointestinal upset: nausea, abdominal discomfort or constipation.

Serious or Rare Side Effects

• Bradycardia: excessively slow heart rate that may require medical attention.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Anaphylaxis: severe allergic reaction with rash, swelling, and difficulty breathing.

When prescribing Metoprolol Tartrate, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status: evaluate heart rate, blood pressure, and signs of heart failure before initiation.
• Review concomitant medications: identify drugs that may potentiate bradycardia or hypotension.
• Monitor renal and hepatic function: dose adjustments may be needed in impairment.
• Caution in asthma or COPD: β1‑selectivity may still affect bronchial tone in sensitive individuals.
• Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Metoprolol Tartrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: combined use can cause excessive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): increase plasma levels of metoprolol, raising risk of cardiac depression.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): markedly raise metoprolol concentrations.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: beta‑blockade may mask hypoglycaemia symptoms, requiring dose adjustments.
• Diuretics: additive blood pressure‑lowering effect may necessitate monitoring.
• Antidepressants (tricyclics): may enhance bradycardic effects.